Hillmen trial of alemtuzumab in first-line chronic lymphocytic leukemia still provides valuable information
- PMID: 18467736
- DOI: 10.1200/JCO.2008.16.3782
Hillmen trial of alemtuzumab in first-line chronic lymphocytic leukemia still provides valuable information
Comment on
-
Have we forgotten the purpose of phase III studies?J Clin Oncol. 2007 Dec 10;25(35):5553-5. doi: 10.1200/JCO.2007.13.7810. Epub 2007 Nov 5. J Clin Oncol. 2007. PMID: 17984184 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
